
Relavo’s PeritoneX reduces infection risk in home peritoneal dialysis, addressing peritonitis and enabling broader PD adoption. This Class 2 device disinfects catheter connections in a closed system. Sold under a monthly subscription, it helps dialysis clinics cut hospitalizations and expand home treatment. Relavo has verified efficacy, earned FDA Safer Technologies acceptance, and secured patents and funding. Proceeds go toward manufacturing, FDA clearance, and limited commercialization. Potential acquirers include Baxter, Fresenius, Terumo, and Angelini Pharma, seeking to integrate PeritoneX for a competitive edge in PD tubing systems and catheter disinfection.
https://relavomedical.com/
To learn more about Relavo, review the items linked below!
The RVC Deep Dive is a 90 minute virtual meeting held between company executive leadership, RVC Investors, and RVC staff. The purpose of this meeting is to cover all major due diligence questions such as business strategy, team, product, competition, IP, market, traction, key risks, and exit strategy.
The structure of the meeting is as follows:
Investor Pitch (15 minutes)
Guided Q&A w/ Investors (75 minutes)
To attend, you must be an accredited investor (net worth of at least one million US dollars, not including the value of one’s primary residence, or have made at least $200,000 each year for the last two years [or $300,000 together with his or her spouse if married] and have the expectation to make the same amount this year). We do not require a minimum investment.